43rd week of 2008 patent applcation highlights part 53 |
Patent application number | Title | Published |
20080261887 | USE OF A PCV2 IMMUNOGENIC COMPOSITION FOR LESSENING CLINICAL SYMPTOMS IN PIGS - The present invention relates to the use of an immunogenic composition that comprises a porcine circovirus type 2 (PCV2) antigen for treatment of several clinical manifestations (diseases). Preferably, the clinical manifestations are associated with a PCV2 infection. Preferably, they include lymphadenopathy, lymphoid depletion and/or multinucleated/giant histiocytes. Moreover, the clinical symptoms include lymphadenopathy in combination with one or a multiple of the following symptoms in pigs: (1) interstitial pneumonia with interlobular edema, (2) cutaneous pallor or icterus, (3) mottled atrophic livers, (4) gastric ulcers, (5) nephritis and (6) reproductive disorders, e.g. abortion, stillbirths, mummies, etc. Furthermore the clinical symptoms include Pia like lesions, normally known to be associated with Lawsonia intracellularis infections. | 2008-10-23 |
20080261888 | Antibodies to PDGF-D - PDGF-D, a new member of the PDGF/VEGF family of growth factors, as well as the nucleotide sequence encoding it, methods for producing it, antibodies and other antagonists to it, transfected and transformed host cells expressing it, pharmaceutical compositions containing it, and uses thereof in medical and diagnostic applications, including methods for stimulating growth of a connective tissue or healing a wound in a mammal, which methods comprise administering to the mammal an effective amount of PDGF-D polypeptides or polynucleotides encoding the PDGF-D polypeptides. | 2008-10-23 |
20080261889 | Method for determining the risk of developing a neurological disease - Methods and kits are provided for determining whether a subject is at risk of developing a neurological disease such as Alzheimer's disease and multiple sclerosis. The methods and kits are based on the detection of one or more nucleic acid variants in the MBL gene of the subject. | 2008-10-23 |
20080261890 | Use of neurotransmitters and neuropeptides for the treatment of dry eye diseases and related conditions - The invention further features novel methods and compositions for treating and preventing dry eye by administration of neurotransmitters and/or neuropeptides, optionally in formulation with various other agents, as well as kits for the use of such novel formulations and methods. | 2008-10-23 |
20080261891 | COMPOSITIONS AND METHODS FOR USING SYRINGOPEPTIN 25A AND RHAMNOLIPIDS - The present invention provides a therapeutic composition having at least one syringopeptin and at least one rhamnolipid so that the composition has one or more of the following activities: antibacterial; antifungal; and antitumor activity. The therapeutic composition includes the following: a therapeutically effective amount of a syringopeptin; a therapeutically effective amount of a rhamnolipid; and a pharmaceutically acceptable carrier. Additionally, the present invention provides a method for inhibiting or treating cancer or a microbial infection in a subject, wherein the method includes the following: providing a subject in need of inhibition or treatment of cancer or a microbial infection; and administering a therapeutic amount of a therapeutic composition to the subject so as to inhibit or treat the cancer or microbial infection. | 2008-10-23 |
20080261892 | Acid Addition Salts of Ac-Phscn-Nh2 - Acid addition salts of Ac—PHSCN—NH | 2008-10-23 |
20080261893 | TOPICAL CORNEAL ANALGESIA USING NEUROTENSIN RECEPTOR AGONISTS AND SYNERGISTIC NEUROTENSIN COMBINATIONS WITHOUT DELAYING WOUND HEALING - A method for administering an ocular analgesic is described. The method includes the steps of providing a topical analgesic that includes a neo-tryptophan-containing neurotensin analog and applying the topical analgesic to the ocular tissue in a dose of about 0.0001 to about 5 mg alternatively about 0.0001 to about 3 mg, alternatively about 0.0005 to about 1.2 mg, alternatively about 0.0005 to about 1.0 mg, alternatively about 0.00075 to about 1.0 mg, alternatively about 0.001 mg to about 1.0 mg, alternatively about 0.001 mg to about 0.8 mg, alternatively about 0.001 mg to about 0.7 mg, alternatively about 0.001 mg to about 0.6 mg. Methods of administering a topical analgesic containing a neo-tryptophan-containing neurotensin analog are also described. The topical analgesic can be administered in a patch, gel, lotion, spray, or mist. | 2008-10-23 |
20080261894 | Combination Therapy with Glatiramer Acetate and Rasagiline for the Treatment of Multiple Sclerosis - The subject invention provides a method of treating a subject afflicted with a form of multiple sclerosis comprising periodically administering to the subject an amount of glatiramer acetate and an amount of rasagiline or the pharmaceutically acceptable salt thereof, wherein the amounts when taken together are effective to alleviate a symptom of the form of multiple sclerosis in the subject so as to thereby treat the subject. The subject invention also provides a package comprising glatiramer acetate, rasagiline or the pharmaceutically acceptable salt thereof and instructions for use of the together to alleviate a symptom of a form of multiple sclerosis in a subject. The subject invention further provides a pharmaceutical combination comprising separate dosage forms of an amount of glatiramer acetate and an amount of rasagiline or the pharmaceutically acceptable salt thereof, which combination is useful to alleviate a symptom of a form of multiple sclerosis in a subject. | 2008-10-23 |
20080261895 | Isolated hydroxy and n-oxide metabolites and derivatives of O-desmethylvenlafaxine and methods of treatment - The present invention provides novel isolated compounds characterized as metabolites or derivatives of desmethylvenlafaxine including hydroxy-DV metabolites, hydroxy-DV-glucuronide metabolites, N-oxide-DV metabolites, and benzyl-hydroxy-DV metabolites. The invention includes pharmaceutical compositions comprising any of the metabolites or derivatives of the invention in combination with a pharmaceutically acceptable carrier or excipient. The invention also includes a method of treating at least one central nervous system disorder in a mammal comprising providing to a mammal in need thereof an effective amount of the compounds of the invention. | 2008-10-23 |
20080261896 | Testosterone generating and metabolizing enhancer - A testosterone generating and metabolizing enhancer is proposed in the invention, which increases concentrations of testosterone in both seminal vesicle and bloodstream, and may further promote the gene expression of metabolizing testosterone into 5α-reductase of dihydrotestosterone. The testosterone generating and metabolizing enhancer of the invention is characterized in that an effective component thereof may be phenylethanoid glycosides; said phenylethanoid glycosides may comprise at least one of echinacoside and acteoside, or may comprise both echinacoside and acteoside, more preferably. The testosterone generating and metabolizing enhancer of the invention may be applied in medicines, substances for external uses on skin, and foods and beverages for mammals (including humans); as well as an animal feed for mammals. | 2008-10-23 |
20080261897 | Formulation Containing a Polyphenol-Containing Composition and Isomaltulose - The present invention relates to formulations containing isomaltulose and a polyphenol-containing composition, uses of same and the use of isomaltulose for masking unwanted taste components, in particular bitter substances, in formulations, in particular in formulations containing tea extracts. | 2008-10-23 |
20080261898 | COMPOSITION AND METHOD FOR CANCER TREATMENT AND PREVENTION - Compounds, compositions, methods and kits are provided for treating, reducing the risk of, or preventing diseases and/or conditions, such as diseases associated with angiogenesis and/or abnormal cell proliferation, such as cancer. Compounds of the present invention have antiangiogenic and anti-cancer activity with minimum toxic effects on normal cells. Methods for preparing and manufacturing the compounds and pharmaceutical compositions are also provided. | 2008-10-23 |
20080261899 | AGENT FOR CONTROLLING Bcl-2 EXPRESSION COMPRISING GINSENOSIDE F1 AS AN ACTIVE COMPONENT - The present invention relates to an agent for controlling Bcl-2 expression comprising ginsenoside F1 (20-O-β-D-glucopyranosyl-20(S)-protopanaxatriol) represented by the following formula 1 as an active component. | 2008-10-23 |
20080261900 | Compositions and Methods for Treating, Reducing, Ameliorating, or Preventing Infections Caused by Antibacterial Drug-Resistant Bacteria - Compositions comprise a fluoroquinolone having Formulae I-VIII for treating, reducing, ameliorating, or preventing infections caused by some bacteria that are resistant to an antibacterial drug. Methods for treating, reducing, ameliorating, or preventing such infections use such compositions. | 2008-10-23 |
20080261901 | Cosmetic Composition Comprising Beta-Fructosyl-L-Ascorbic Acid for Skin Whitening - The present invention is related to novel cosmetic composition comprising β-fructosyl-L-ascorbic acid derivatives produced by fructose conversion reaction using by ascorbic acid and the compounds shows potent inhibiting effect on the activity of tyrosinase enzyme, therefore, it can be useful as a skin whitening cosmetic composition as an cream, skin, lotion, pack and the like. | 2008-10-23 |
20080261902 | Pharmaceutical composition containing polydatin and its application - A composition includes polydatin and solvent for dissolving the polydatin, wherein the solvent comprises alcohol in a range between 40 and 95% by volume, propanediol in a range between 0 and 60% by volume, and water in remaining volume. The concentration of the polydatin must be at least 6 mg/ml. The composition has good stability in cold preservation. The composition is in a pharmaceutically acceptable administrative form selected from the group consisting of an intravenous injection, and intramuscular injection, an oral administration, a spray solution, and an aerosol form. | 2008-10-23 |
20080261903 | Regulation of Kinase, Regulated in Copd Kinase (Rc Kinase) - Reagents which regulate human RC Kinase activity and reagents which bind to human RC Kinase gene products can be used to regulate this protein for therapeutic effects. Such regulation is particularly useful for treating chronic obstructive pulmonary disease, asthma, cancer, and diseases in which cell signaling is defective. | 2008-10-23 |
20080261904 | Chimeric Gapped Oligomeric Compounds - The present invention provides double stranded compositions wherein the first strand comprises three different regions and the second strand is native RNA. Each region has native or modified ribofuranosyl sugar moieties that are different than those of the other two regions. At least a portion of the first oligomeric compound is complementary to and hybridizes to a nucleic acid target. The present invention also provides methods for modulating gene expression using the modified oligomeric compounds and compositions of oligomeric compounds. | 2008-10-23 |
20080261905 | Modified Nucleosides for Rna Interference - The present invention relates to the use of modified nucleotides and single or double stranded oligonucleotides having at least one of said modified nucleotides for performing RNA interference. The modified nucleotides are selected from 6-membered ring containing nucleotides such as hexitol, altritol, O-substituted or O-alkylated altritol, cyclohexenyl, ribo-cyclohexenyl and O-substituted or O-alkylated ribo-cyclohexenyl nucleotides. The present invention also relates to novel modified nucleosides or nucleotides and to the use of the novel modified nucleosides and nucleotides in single or double stranded oligonucleotides for RNA interference, antisense therapy or other applications. | 2008-10-23 |
20080261906 | METHODS AND COMPOSITIONS FOR IDENTIFYING ANTI-HCV AGENTS - The invention features methods and compositions for screening for agents that modulate replication of a virus, particularly Flaviviridae virus (particularly hepatitis C virus (HCV)), where the methods provide for detection of agents that modulate the binding of TBC and NS5A, the inhibition of TBC activity, inhibition of Rab1 activity, and/or the expression of the TBC protein and/or Rab1 protein. The invention also features methods of controlling viral replication, and agents useful in such methods. | 2008-10-23 |
20080261907 | COMPOSITIONS AND METHODS OF SPHINGOSINE KINASE INHIBITORS IN RADIATION THERAPY OF VARIOUS CANCERS - The present invention relates to Sphingosine kinase inhibitors that are useful for treating various cancers. The invention further relates to compositions and methods of SPK inhibitors, including siRNAs, which specifically block gene expression of SPK and potentiates the effect of radiation in the treatment of various cancers. | 2008-10-23 |
20080261908 | MicroRNA-based methods and compositions for the diagnosis, prognosis and treatment of breast cancer - The present invention provides novel methods and compositions for the diagnosis, prognosis and treatment of breast cancer. The invention also provides methods of identifying anti-breast cancer agents. | 2008-10-23 |
20080261909 | Gene Delivery to Organs - Application of a virus with poloxamer alone onto atria results in diffuse epicardial gene transfer with negligible penetration into the myocardium. Progressive increases in protease concentration, however, allow transmural gene transfer. After protease exposure, echocardiographic left atrial diameter does not change. Left atrial ejection fraction decreases on post-operative day 3, but returns to baseline by day 7. At appropriate protease concentrations, tissue tensile strength is unaffected by the procedure. Transmural atrial gene transfer can be effected using this direct “painting” method. | 2008-10-23 |
20080261910 | Diagnostic Methods Based on Polymorphisms of Glucosyltransferase-Like Protein - The present invention arises from the identification of an association between the gene encoding glucosyltransferase-like protein (GT) and osteoarthritis (OA). It therefore relates to diagnostic techniques for determining a patient's susceptibility to develop OA by detecting all or part of the GT gene, its precursors or products (mRNA, cDNA, genomic DNA, or protein). In particular, the invention relates to methods and materials for analysing allelic variation in the GT gene, and to the use of GT polymorphisms in the identification of an individuals' risk to develop OA. The invention is also directed to methods for identifying modulators of OA, which modulate the GT gene or its encoded protein. | 2008-10-23 |
20080261911 | Uses of diphenyl/diphenylamine carboxylic acids - The present invention demonstrates that chemical-induced degradation of Sp proteins by a specific sub-class of non-steroidal anti-inflammatory drugs inhibited cancer cell growth, angiogenesis and metastasis of cancer cells. The inhibitory effects of these compounds were demonstrated in vitro and in vivo. Hence, the results discussed herein indicate that these compounds can be used to inhibit cell growth, angiogenesis, and metastasis in cancers such as pancreatic cancer, esophageal cancer, breast cancer, prostate cancer, colon cancer, bladder cancer, and ovarian cancer. | 2008-10-23 |
20080261912 | Bispecific Antisense Oligonucleotides that Inhibit IGFBP-2 and IGFBP-5 and Methods of Using Same - Bispecific antisense oligonucleotides which consist essentially of a sequence of bases that is complementary to portions of both the gene encoding human IGFBP-2 and the gene encoding human IGFBP-5 are useful in as antisense therapeutics in the treatment of endocrine-regulated cancers. | 2008-10-23 |
20080261913 | Compounds and pharmaceutical compositions for the treatment of liver disorders - Provided herein are compounds, compositions and methods for the treatment of liver disorders, including liver cancer and metabolic diseases, such as diabetes, hyperlipidemia, atherosclerosis, and obesity. Specifically, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-cancer agents. | 2008-10-23 |
20080261914 | STABILIZATION OF VITAMIN B12 - The invention relates to preparations comprising vitamin B | 2008-10-23 |
20080261915 | Wound-Healing Pharmaceutical Compositions in the Form of a Sterile Powder Based on Amino Acids and Sodium Hyaluronate - This invention relates to wound-healing pharmaceutical compositions in the form of a sterile powder based on amino acids and sodium hyaluronate. | 2008-10-23 |
20080261916 | Synergistic Prebiotic Compositions - The invention relates to synergistic compositions comprising prebiotic components selected from fructose polymers GF | 2008-10-23 |
20080261917 | Isoindolin-1-One Derivatives - A compound of formula | 2008-10-23 |
20080261918 | Silicon Compounds and Their Use - A compound of any of formulas (I) to (V): wherein at least one of Y and Z includes a Si atom, is of utility in therapy. | 2008-10-23 |
20080261919 | Camptothecin-analog with a novel, "flipped" lactone-stable, E-ring and methods for making and using same - The present invention discloses: (i) a novel, lactone-stable, “flipped” E-ring camptothecin, pharmaceutically-acceptable salts, and/or analogs thereof; (ii) methods of synthesis of said novel, lactone-stable, “flipped” E-ring camptothecin, pharmaceutically-acceptable salts, and/or analogs thereof; (iii) pharmaceutically-acceptable formulations comprising said novel, lactone-stable, “flipped” E-ring camptothecin, pharmaceutically-acceptable salts, and/or analogs thereof, and, optionally, one or more additional chemotherapeutic agents; (iv) methods of administration of said novel, lactone-stable, “flipped” E-ring camptothecin, pharmaceutically-acceptable salts, and/or analogs thereof, and, optionally, one or more additional chemotherapeutic agents, to subjects in need thereof; and (v) devices for the administration of said novel, lactone-stable, “flipped” E-ring camptothecin, pharmaceutically-acceptable salts, and/or analogs thereof, and, optionally, one or more chemotherapeutic agents, to subjects in need thereof. | 2008-10-23 |
20080261920 | 2-Aminooxazolines as TAAR1 ligands - The invention relates to compounds of formula I | 2008-10-23 |
20080261921 | FUSED RING HETEROCYCLE KINASE MODULATORS - The present invention provides fused ring heterocycles as kinase modulators, pharmaceutical compositions containing these modulators, and methods of using these modulators to treat diseases mediated by kinase activity. | 2008-10-23 |
20080261922 | Pharmacological Treatments for Sleep Disorders (Apnoe) With Prostanoid Receptor Antagonists - This invention is directed to methods for preventing or ameliorating sleep-related breathing disorders. The method comprises administration to a patient in need thereof an effective dose of one or a combination of prostanoid receptor antagonists (eg. ramatroban, ifetroban, diphloretin, phosphate, polyphloretin phosphate, seratrodast, SC19220). The prostanoid receptor antagonist or combination of prostanoid receptor antagonists can be administered in conjunction with one or more serotonin receptor agonists, one or more cannabinoids receptor agonists, one or more serotonin reuptake inhibitors, one or more noradrenalin reuptake inhibitors, a combination of reuptake inhibitors, an inhibitor of prostanoid synthesis, or any combination of the foregoing. | 2008-10-23 |
20080261923 | Alkene Mimics - Ac-Phe-Tyr-phosphoSer-Ψ[CH═C]-Pro-Arg-NH | 2008-10-23 |
20080261924 | METHOD FOR THE TREATMENT OF BONE DISORDERS - Disclosed are methods for treating bone disorders in mammals. The methods comprise a loading period with a bisphosphonate followed by a maintenance period. The loading dose is two to twenty times per day greater than the corresponding maintenance dose. Also disclosed are compositions and kits for implementing the methods disclosed herein. | 2008-10-23 |
20080261925 | COMPOUNDS, COMPOSITIONS, KITS AND METHODS OF USE TO ORALLY AND TOPICALLY TREAT ACNE AND OTHER SKIN CONDITIONS BY ADMINISTERING A 19-NOR CONTAINING VITAMIN D ANALOG WITH OR WITHOUT A RETINOID - Oral and topical pharmaceutical compositions, kits and methods of treatment thereof for treating various skin disorder including acne, psoriasis, ichthyosis, photoaging, photodamaged skin, and, skin cancer. Exemplary vitamin D analogs as active pharmaceutical ingredients include 2-methylene-19-nor-20(S)-1α-hydroxy-bishomopregnacalciferol, 19-nor-26,27-dimethylene-20(S)-2-methylene-1α,25-dihydroxyvitamin D | 2008-10-23 |
20080261926 | Pharmaceutical Calcimimetics - This invention relates to novel calcimimetic compounds, their derivatives, pharmaceutically acceptable salts, solvates, and hydrates thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by binding to, and modulating the sensitivity of, calcium receptors on the parathyroid gland. | 2008-10-23 |
20080261927 | Stable Aqueous Suspension - An aqueous suspension of a hydrophobic nutrient is disclosed. In particular, the nutrient, in ester form, is combined with a selected dispersion aid and a dispersion agent(s), and then dispersed in an aqueous medium to form the suspension. | 2008-10-23 |
20080261928 | Method of Treating Human Preeclampsia Employing Resibufagenin - A method of treating preeclampsia including administering a therapeutically effective dose of resibufagenin to a patient having preeclampsia. Effecting the determination of the presence of preeclampsia may be by determining whether there has been a substantial elevation in marinobufagenin which may be blood-derived or urine-derived and if such elevation does exist, concluding that preeclampsia does exist. The method may advantageously be practiced by employing urine, blood serum or blood plasma as the body specimen containing the protein in determining whether a patient has preeclampsia. In another embodiment, bufodienolide derivatives other than resibufagenin may be employed in lieu of thereof or in combination therewith. In another embodiment, resibufagenin analogues may be employed in the treatment of preeclampsia. | 2008-10-23 |
20080261929 | COMBINATION OF PROGESTERONE-RECEPTOR ANTAGONIST TOGETHER WITH AN AROMATASE INHIBITOR FOR USE IN BRCA MEDIATED DISEASES - The present invention relates to the combination of the progesterone-receptor antagonist 11β-(4-acetylphenyl)-17β-hydroxy-17α-(1,1,2,2,2-pentafluoroethyl)-estra-4,9-dien-3-one or a pharmaceutically acceptable derivative or analogue thereof, together with at least one aromatase inhibitor and to the use of said combination for the prophylaxis and treatment of BRCA1- or BRCA2-mediated diseases. Aromatase inhibitors which can be combined together with the compound 11β-(4-acetylphenyl)-17β-hydroxy-17α-(1,1,2,2,2 pentafluoroethyl)-estra-4,9-dien-3-one are for example aminoglutethimide, fadrozole, anastrozole, letrozole, vorozole, formestane, exemestane and atamestane. | 2008-10-23 |
20080261930 | ENHANCEMENT OF ACTIVITY AND/OR DURATION OF ACTION OF SELECTED ANTI-INFLAMMATORY STEROIDS FOR TOPICAL OR OTHER LOCAL APPLICATION - Methods and compositions for enhancing the activity and/or duration of action of soft anti-inflammatory steroids of the haloalkyl 17α-alkoxy-11β-hydroxyandrost-4-en-3-one-17β-carboxylate type and the corresponding Δ | 2008-10-23 |
20080261931 | Method and Means of Preventing and Treating Sleep Disordered Breathing - A method of treating or preventing snoring, obstructive sleep apnea (OSA) and/or central sleep apnea (CSA) comprises administering a pharmacologically effective amount a salt of acetylhomotaurine (AcHT) such as calcium acamprosate (CA) to a patient. Also disclosed is the use of AcHT and CA for the manufacture of a medicament for treating or preventing snoring, OSA and/or CSA and of a diagnostic device, kit or composition; a protective patch comprising AcHT or CA; and a pharmaceutical composition comprising AcHT or CA and an agent capable of alleviating the effects of snoring OSA and/or CSA, in combined amounts effective in the treatment of snoring OSA and/or CSA, and a carrier. | 2008-10-23 |
20080261932 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND/OR TREATMENT OF AN EXACERBATION OF ASTHMA - The present invention relates to the use of a composition comprising:
| 2008-10-23 |
20080261933 | COMBINATION OF PROGESTERONE-RECEPTOR ANTAGONIST TOGETHER WITH A LUTEIN-HORMONE-RELEASING HORMONE AGONIST AND ANTAGONIST FOR USE IN BRCA MEDIATED DISEASES - The present invention relates to the combination of the progesterone-receptor antagonist 11β-(4-acetylphenyl)-17β-hydroxy-17α-(1,1,2,2,2-pentafluoroethyl)-estra-4,9-dien-3-one or a pharmaceutically acceptable derivative or analogue thereof, together with at least one lutein-hormone-releasing hormone agonist or antagonist and to the use of said combination for the prophylaxis and treatment of BRCA1- or BRCA2-mediated diseases. Lutein-hormone-releasing hormone agonists and antagonists, which can be combined together with the compound 11β-(4-acetylphenyl)-17β-hydroxy-17α-(1,1,2,2,2 pentafluoroethyl)-estra-4,9-dien-3-one are for example gonadorelin, goserelin, triptorelin, buserelin, nafarelin, deslorelin, histrelin, antide, ramorelix, cetrorelix, antarelix, ORG30850, abarelix, ganirelix and leuprolin. | 2008-10-23 |
20080261934 | Dosage Form for Hormonal Contraception - A dosage form for hormonal contraception containing a specific number of gestagen-containing daily units A and a specific number of gestagen-containing daily units B for uninterrupted, daily, oral administration of daily units A and then immediately subsequently of daily units B, wherein the daily units A in each case contain at most 200 μg of folic acid and the daily units B contain >200 μg up to the maximum permissible amount of folic acid for women. | 2008-10-23 |
20080261935 | 2" OXO-VORUSCHARIN AND DERIVATIVES THEREOF - Compounds and pharmaceutical compositions which include 2″ oxo-voruscharin and derivatives are disclosed. The compounds and pharmaceutical compositions are useful in methods of treating cancer, particularly pancreatic cancer. | 2008-10-23 |
20080261936 | METHODS OF REDUCING THE BODY WEIGHT OF A SUBJECT BY ADMINISTERING A FATTY ACID ESTER OF AN ESTROGEN OR ESTROGEN DERIVATIVE IN AN OIL AND COMPOSITIONS CONTAINING THE SAME - Compositions and methods for reducing the body weight of a subject are disclosed. The invention is directed to methods for reducing the body weight in a subject comprising administering therapeutically effective amounts of a fatty acid ester of an estrogen or estrogen derivative in an oil. Furthermore the invention is directed to compositions for reducing the body weight in a subject comprising administering therapeutically effective amounts of a fatty acid ester of an estrogen or estrogen derivative in an oil. | 2008-10-23 |
20080261937 | PHARMACEUTICAL COMPOSITIONS AND METHOD FOR TREATING PEDIATRIC HYPOGONADISM - The present invention relates to compositions for treating prepubertal males of adolescent age with insufficient testosterone production using a hydroalcoholic testosterone gel formulation that provides, among other things, a desirable pharmacokinetic hormone profile, and methods of treating said adolescent males. | 2008-10-23 |
20080261938 | Tetracyclic Indole Derivatives as Antiviral Agents - The present invention relates to tetracyclic indole compounds of formula (I); wherein R | 2008-10-23 |
20080261939 | STANNSOPORFIN COMPOSITIONS AND ADMINISTRATION - Pharmaceutical compositions including stannsoporfin, drug products incorporating pharmaceutical compositions, methods of making pharmaceutical compositions, and methods of treating hyperbilirubinemia with drug products and compositions are disclosed. | 2008-10-23 |
20080261940 | N-(1-Arylpyrazol-4L) Sulfonamides and their Use as Parasiticides - The invention relates to a sulfonamide compound of formula (I) or a pharmaceutically, veterinarily or agriculturally acceptable salt or solvate thereof, where the groups R | 2008-10-23 |
20080261941 | Biaryl Ether Urea Compounds - The present invention relates to compounds of Formula (I) | 2008-10-23 |
20080261942 | COMBINATIONS OF BILE ACID SEQUESTRANT(S) AND STEROL ABSORPTION INHIBITOR(S) AND TREATMENTS FOR VASCULAR INDICATIONS - The present invention provides compositions, therapeutic combinations and methods including: (a) at least one bile acid sequestrant; and (b) at least one substituted azetidinone or substituted β-lactam sterol absorption inhibitor which can be useful for treating vascular conditions, diabetes, obesity and lowering plasma levels of sterols. | 2008-10-23 |
20080261943 | PYRROLOPYRIMIDINE A2B SELECTIVE ANTAGONIST COMPOUNDS, THEIR SYNTHESIS AND USE - The subject invention provides compounds having the structure: | 2008-10-23 |
20080261944 | Indole Derivatives as Antiviral Agents - The present invention relates to indole compounds of the formula (I): wherein R | 2008-10-23 |
20080261945 | Compounds Having Activity at Nk3 Receptor and Uses Thereof in Medicine - The present invention relates to compounds of formula (I), a pharmaceutically acceptable salt, solvate or prodrug thereof: | 2008-10-23 |
20080261946 | Pyrimidine Compounds for the Treatment of Inflammatory Disorders - The present invention relates to novel pyrimidine compounds, for the modulation of the histamine H4 receptor and the treatment or prevention of conditions mediated by the histamine H4 receptor. The invention also relates to the preparation of such compounds. | 2008-10-23 |
20080261947 | FUSED PYRIDAZINE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT - Fused pyridazine derivatives represented by formula (I) or pharmaceutically acceptable salts thereof (wherein each symbol has the meaning as defined in the specification.). | 2008-10-23 |
20080261948 | Ligands for G-Protein Coupled Receptors - The invention provides compounds of general formulae I-IV or pharmaceutically acceptable salts thereof: | 2008-10-23 |
20080261949 | CYCLOHEXYL(ALKYL)PROPANOLAMINES, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME - The present invention relates to the compounds of formula (I): | 2008-10-23 |
20080261950 | Compounds that inhibit cholinesterase - Compounds that inhibit cholinesterase activity and, upon hydrolysis release a pharmacologically active agent. The compounds of the invention are employed in methods to treat an individual. The pharmacologically active agent obtained by hydrolysis of the compound can treat, for example, a nervous system condition, a cholinergic deficiency and conditions or diseases associated with a deficiency in a pharmacologically active agent, such as acetylcholine. | 2008-10-23 |
20080261951 | Condensed azepines as vasopressin agonists - This invention provides novel compounds according to general formula (1) wherein A is a bicyclic or tricyclic azepine derivative, V | 2008-10-23 |
20080261952 | Aryl Urea Derivatives for Treating Obesity - A method of treating a condition associated with the CB-1 receptor, in particular obesity, by administering an effective amount of an aryl urea CB-1 receptor modulating compound to a subject in need of such treatment. | 2008-10-23 |
20080261953 | Compounds, Compositions and Methods of Inhibiting Alpha-Synuclein Toxicity - Compounds and compositions are provided for treatment or amelioration of one or more symptoms of α-synuclein toxicity, α-synuclein mediated diseases or diseases in which α-synuclein fibrils are a symptom or cause of the disease. In one embodiment, the compounds for use in the compositions and methods are heteroaryl acylguanidines, heteroarylhydrazones, dihy-dropyridones, heteroaryl and aryl styryl ketones, and heteroarylpyrazoles. | 2008-10-23 |
20080261954 | Cholinergic Enhancers with Improved Blood-Brain Barrier permeability for the Treatment of Diseases Accompanied by Cognitive Impairment - The present invention refers to compounds that, in addition to enhancing the sensitivity to acetylcholine and choline, and their exogenous agonists, of neuronal cholinergic receptors and/or acting as cholinesterase inhibitors and/or neuroprotective agents, have enhanced blood-brain barrier permeability in comparison to their parent compounds. The compounds are derived (either formally by their chemical structure or directly by chemical synthesis) from natural compounds belonging to the class of amaryllidaceae alkaloids e.g. Galanthamine, narwedine and lycoramine, or from metabolites of said compounds. | 2008-10-23 |
20080261955 | Use of Pharmaceutical Compositions of Lofepramine for the Treatment of Adhd, Cfs, Fm and Depression - In accordance with the present invention, it has been discovered that compounds exhibiting activity as a potent noradrenaline reuptake inhibitor (e.g., a NA:5HT ratio of greater than or equal to about 1000:1), and activity at the dopamine D2 receptor sites (e.g., lofepramine) are effective in the treatment and prevention of various diseases and disorders associated with noradreanaline reuptake, such as ADHD, CFS, fibromyalgia, and depression with pain. | 2008-10-23 |
20080261956 | Substituted Phenols as Active Agents Inhibiting Vegf Production - The present invention relates to methods, compounds, and compositions for inhibiting angiogenesis. More particularly, the present invention relates to methods, compounds, and compositions for inhibiting VEGF production. | 2008-10-23 |
20080261957 | DIHYDRO-BENZO[B][1,4]DIAZEPIN-2-ONE SULFONAMIDE DERIVATIVES - The present invention relates to compounds of formula (I), a process for the manufacture thereof, their use for the preparation of medicaments for treating CNS disorders and pharmaceutical compositions containing them. Compounds of formula (I) are represented by general formula (I) | 2008-10-23 |
20080261958 | Combination of Organic Compounds - The present invention relates to a combination comprising: (a) an angiotensin II receptor blocker (ARB), or a pharmaceutically acceptable salt thereof; (b) a calcium channel blocker (CCB), or a pharmaceutically acceptable salt thereof; and (c) one of the two active agents selected from (i) a rennin inhibitor, or a pharmaceutically acceptable salt thereof; and (ii) a neutral endopeptidase (NEP) inhibitor, or a pharmaceutically acceptable salt thereof; for the prevention of, delay the onset of and/or treatment of cardiovascular disorders, which method comprises administering to a warm-blooded animal, in need thereof, a therapeutically effective amount of a combination of the present invention. | 2008-10-23 |
20080261959 | Novel crystalline forms of (S)-N-(1-Carboxy-2-methyl-prop-1-y)-N-pentanoyl-N[2'-(1H-tetrazol-5-yl)bi-phenyl-4-ylmethyl]-amine - This invention relates to novel crystalline forms of valsartan, namely Form A, Form B, Form C, Form D and their solvates thereof. Processes for the preparation of the novel forms are also provided. The present invention further relates to novel processes for preparing a stable amorphous form of valsartan, and in this connection, to the amorphous form of valsartan produced by such processes. The present invention also discloses a novel process for obtaining stable Form I crystals of valsartan. | 2008-10-23 |
20080261960 | Biologically active methylene blue derivatives - The present invention relates to a phenothiazinium compound of Formula (I): | 2008-10-23 |
20080261961 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFIC DISEASES AND OTHER PROLIFERATIVE DISEASES - Compounds of the present invention find utility in the treatment of mammalian cancers and especially human cancers including but not limited to malignant, melanomas, glioblastomas, ovarian cancer, pancreatic cancer, prostate cancer, lung cancers, breast cancers, kidney cancers, cervical carcinomas, metastasis of primary tumor sites, myeloproliferative diseases, leukemias, papillary thyroid carcinoma, non small cell lung cancer, mesothelioma, hypereosinophilic syndrome, gastrointestinal stromal tumors, colonic cancers, ocular diseases characterized by hyperproliferation leading to blindness including various retinopathies, rheumatoid arthritis, asthma, chronic obstructive pulmonary disease, mastocyctosis, mast cell leukemia, a disease caused by c-Abl kinase, oncogenic forms thereof, aberrant fusion proteins thereof and polymorphs thereof, or a disease caused by c-Kit kinase, oncogenic forms thereof, aberrant fusion proteins thereof and polymorphs thereof. | 2008-10-23 |
20080261962 | METHOD OF INHIBITION OF RESPIRATORY DEPRESSION USING POSITIVE ALLOSTERIC AMPA RECEPTOR MODULATORS - The invention is directed to a method for alleviating respiratory depression in a subject as a result of disease of pharmacological agents such as opiates, opioids or barbiturates. The invention also discloses pharmaceutical compositions for use with the method, the composition containing in combination, an analgesic, anaesthetic, or a sedative and a positive allosteric AMPA receptor modulator in an amount sufficient to reduce or inhibit respiratory depression caused by the analgesic, anaesthetic, or sedative. | 2008-10-23 |
20080261963 | SUBSTITUTED QUINOBENZOXAZINE ANALOGS - The present invention relates to quinobenzoxazines analogs having the general formula: | 2008-10-23 |
20080261964 | Substituted quinolones II - The invention relates to substituted quinolones of formula (I) and to methods for their preparation as well as their use for the production of medicaments for the treatment and/or prophylaxis of diseases, especially for use as antiviral agents, in particular against cytomegaloviruses. | 2008-10-23 |
20080261965 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFIC DISEASES AND OTHER PROLIFERATIVE DISEASES - Compounds of the present invention find utility in the treatment of mammalian cancers and especially human cancers including but not limited to malignant, melanomas, glioblastomas, ovarian cancer, pancreatic cancer, prostate cancer, lung cancers, breast cancers, kidney cancers, cervical carcinomas, metastasis of primary tumor sites, myeloproliferative diseases, leukemias, papillary thyroid carcinoma, non small cell lung cancer, mesothelioma, hypereosinophilic syndrome, gastrointestinal stromal tumors, colonic cancers, ocular diseases characterized by hyperproliferation leading to blindness including various retinopathies, rheumatoid arthritis, asthma, chronic obstructive pulmonary disease, mastocyclosis, mast cell leukemia, a disease caused by c-Abl kinase, oncogenic forms thereof, aberrant fusion proteins thereof and polymorphs thereof, or a disease caused by c-Kit kinase, oncogenic forms thereof, aberrant fusion proteins thereof and polymorphs thereof. | 2008-10-23 |
20080261966 | BIS-ARYL SULFONAMIDES - Compounds are provided that act as potent antagonists of chemokine receptors. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of chemokine receptor-mediated diseases, and as controls in assays for the identification of chemokine antagonists. | 2008-10-23 |
20080261967 | Modulators of Central Nervous System Neurotransmitters - Disclosed are agents having pharmacological activity against cellular receptors and intracellular signaling, particularly receptors and signaling pathways of central nervous system (CNS) neurotransmitters. Also disclosed are related methods and compositions for the treatment or prevention of diseases or disorders using the agents. | 2008-10-23 |
20080261968 | Heterobicyclic metalloprotease inhibitors - The present invention relates generally to azabicyclic containing pharmaceutical agents, and in particular, to azabicyclic metalloprotease inhibiting compounds. More particularly, the present invention provides a new class of azabicyclic MMP-3, MMP-8 and/or MMP-13 inhibiting compounds, which exhibit an increased potency and selectivity in relation to currently known MMP-13, MMP-8 and MMP-3 inhibitors. | 2008-10-23 |
20080261969 | 1,4-Dihydropyridine-Fused Heterocycles, Process for Preparing the Same, Use and Compositions Containing Them - This invention relates to compounds of formula (I) | 2008-10-23 |
20080261970 | Sufonamides and Uses Thereof - Compounds of formula (I), including methods of making and methods of using are described in formula (I). | 2008-10-23 |
20080261971 | Novel Heterocyclic Nf-Kb Inhibitors - The present invention relates to compounds of the general formula (I) and salts and physiologically functional derivatives thereof, (I) wherein R | 2008-10-23 |
20080261972 | Cgrp Receptor Antagonists - Compounds of Formula (I), (where variables R | 2008-10-23 |
20080261973 | Sulphonamidoaniline Derivatives Being Janus Kinase Inhibitors - The invention relates to sulphonamidoanilines of formula I, | 2008-10-23 |
20080261974 | Novel Chemical Compounds - This invention relates to newly identified compounds for inhibiting hYAK3 proteins and methods for treating diseases associated with the imbalance or inappropriate activity of hYAK3 proteins. | 2008-10-23 |
20080261975 | Tec Kinase Inhibitors - Disclosed are compounds of formula (I): | 2008-10-23 |
20080261976 | NOVEL PIPERIDINECARBOXAMIDE DERIVATIVES, METHOD FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME - The invention relates to compounds of formula (I): | 2008-10-23 |
20080261977 | Pyrimidine Derivatives as Cannabinoid Receptor Modulators -
The present invention relates to novel pyrimidine derivatives such as compounds of the formula (I) and the use of such compounds or pharmaceutical compositions thereof in the treatment of diseases, particularly pain, which are mediated by the activity of the cannabinoid 2 receptor. | 2008-10-23 |
20080261978 | Chemokine receptor modulators - The invention provides compounds of Formula (I) | 2008-10-23 |
20080261979 | Phenyl-1,2,4-Oxadiazolone Derivatives, Processes For Their Preparation and Methods For Their Use as Pharmaceuticals - The inventive compounds of the present invention are comprised of phenyl and pyridinyl-1,2,4-oxadiazolone derivatives and their physiologically acceptable salts and functional derivatives that are shown to provide peroxisome proliferator activator receptor (PPARdelta) agonist activity. The compounds of the present invention are comprised of the formula: | 2008-10-23 |
20080261980 | Use of Thiazolidinone Derivatives as Antiangiogenic Agents - The invention relates to the use of compounds of general formula (I), in which R | 2008-10-23 |
20080261981 | NOVEL DERIVATIVES OF AMINO ACIDS FOR TREATMENT OF OBESITY AND RELATED DISORDERS - Novel amino acid derivatives are provided that are useful for management of disorders such as obesity and immunological diseases. The derivatives are also useful in lowering blood glucose levels in hyperglycemic disorders and for treating related disorders such as body weight gain, elevated free fatty acid, cholesterol and triglyceride levels and other disorder exacerbated by obesity. | 2008-10-23 |
20080261982 | STILBENE DERIVATIVES AS NEW CANCER THERAPEUTIC AGENTS - Stilbene derivatives exhibit killing and suppression of growth activity against a variety of cancer cells, and are effective at suppressing tumor growth in vivo. The stilbene derivatives may be used in the treatment of diseases characterized by cell hyperproliferation including human malignancies and non-malignant diseases such as liver cirrhosis. Stilbenes may also disrupt abnormal vessels in tumor to achieve vascular disrupting effect to suppress tumor growth. Water soluble pro-drug forms of stilbene derivatives are particularly useful in suppressing tumor growth in vivo. | 2008-10-23 |
20080261983 | Substituted morpholinyl compounds - This disclosure relates to novel substituted morpholinyl compounds and their derivatives, pharmaceutically acceptable salts, solvates, and hydrates thereof. This disclosure also provides compositions comprising a compound of this disclosure and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a 5HT4 serotonin receptor agonist. | 2008-10-23 |
20080261984 | Use of S,S-Reboxetine in the Treatment of Pain - Use of (S,S)- or racemic reboxetine or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of a pain condition selected from neuropathic pain, nociceptive pain, cancer pain, back pain, inflammatory pain, musculo-skeletal disorders, visceral pain, pain from strains/sprains, post-operative pain, posttraumatic pain, burns, renal colic, acute pain, central nervous system trauma, head pain, and orofacial pain, is disclosed. Use of (S,S)-reboxetine or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of pain in a patient refractory to an alpha-2-delta ligand, and use of (S,S)- or racemic reboxetine or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for use as a mental performance or mood enhancer, are also disclosed. | 2008-10-23 |
20080261985 | SYNTHESIS AND BIOLOGICAL ACTIVITIES OF NEW TRICYCLIC-BIS-ENONES (TBES) - This invention describes novel tricyclic-bis-enone derivatives (TBEs), such as TBE-31, TBE-34, TBE-45 and water-soluble TBEs. The methods of preparing these compounds are also disclosed. The inventors demonstrate the ability of these new TBEs to inhibit proliferation of human myeloma cells, inhibit the induction of iNOS in cells stimulated with interferon-γ, induce heme oxygenase-1 (HO-1), induce CD11b expression—a leukemia differentiation marker, inhibit proliferation of leukemia cells, induce apoptosis in human lung cancer, and induce apoptosis in other cancerous cells. The TBEs of this invention are expected to be useful agents for the treatment and prevention of many diseases, including cancer, neurological disorders, inflammation, and pathologies involving oxidative stress. | 2008-10-23 |
20080261986 | PHARMACEUTICAL FORMULATIONS FOR IONTOPHORETIC DELIVERY OF AN ANTI-FUNGAL DRUG - Pharmaceutical formulations suitable for iontophoresis thereof that provide enhanced iontophoretic delivery of an anti-fungal drug to at least one body surface are described. Also described are pharmaceutical formulations suitable for iontophoresis comprising terbinafine and methods for administering terbinafine to a body surface via iontophoresis. In one embodiment, the body surface includes a nail plate and/or the skin. | 2008-10-23 |